Neurotech Publishes PANS Trial Data in High-Impact Journal Neurotherapeutics

Neurotech International (ASX: NTI) has announced the peer-reviewed publication of clinical and mechanistic data for its proprietary drug NTI164 in Neurotherapeutics, the official journal of the American Society for Experimental NeuroTherapeutics. The publication presents results from a Phase I/II trial in Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), demonstrating both clinical efficacy and detailed molecular evidence of how NTI164 modulates key immune and epigenetic pathways.

The study evaluated 14 children with chronic, relapsing PANS who received NTI164 at 20 mg/kg/day over 12 weeks. Published in a journal with an Impact Factor of 6.9, the data represents the first treatment to show both efficacy and biological pathway modulation in PANS, a severe neuroimmune disorder with no currently approved treatments. For investors, peer-reviewed publication in a high-impact journal de-risks the development pathway and strengthens NTI164’s regulatory and commercial positioning.

What Does the NTI164 Neurotherapeutics Publication Mean for Shareholders?

Peer-reviewed publication in a high-impact scientific journal carries material significance beyond general corporate announcements. For (ASX: NTI), this publication validates the quality and rigour of the clinical data underpinning NTI164’s development programme.

Scientific publications undergo independent expert review before acceptance, providing third-party validation of methodology, data integrity, and conclusions. Regulatory agencies reference peer-reviewed publications in their assessment processes, particularly for orphan indications where limited precedent exists. The publication strengthens Neurotech’s regulatory submissions by demonstrating that independent scientific experts have scrutinised and endorsed the findings.

From a partnership perspective, pharmaceutical companies conducting due diligence place considerable weight on published data. High-impact journal publication signals scientific credibility and reduces perceived technical risk for potential collaborators evaluating in-licensing or co-development opportunities.

“This publication represents another key piece of validation for Neurotech and NTI164. As previously disclosed, the results of the Phase I/II clinical trial in PANS not only demonstrates meaningful clinical improvements in children with PANS, but also provide detailed molecular evidence that NTI164 modulates key immune and epigenetic pathways implicated in the disease,” said Dr Anthony Filippis, Managing Director and CEO.

“Having both clinical outcomes and mechanistic data reported in a high-quality, peer-reviewed journal strengthens the scientific foundation of NTI164 and supports its continued development across PANS and other neuroinflammatory paediatric indications.”

The mechanistic data component is particularly material. Demonstrating a reproducible, explainable biological mechanism supports patent protection claims, enables biomarker development for patient selection, and provides scientific rationale for expansion into related conditions.

Understanding PANS: The Condition Behind the Study

Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is a severe neuroimmune disorder characterised by the abrupt onset of obsessive-compulsive disorder, anxiety, tics, cognitive decline, and behavioural regression. The condition typically manifests suddenly in children, often triggered by infection.

PANS differs from gradual-onset neuropsychiatric conditions in both its presentation and underlying biology. The acute nature of symptom onset suggests an immune-mediated process, where the body’s immune response affects brain function. Children with PANS experience substantial impairment across multiple domains, affecting academic performance, social functioning, and quality of life.

Currently, there are no approved treatments specifically for PANS. This positions the indication as an orphan disease opportunity, offering regulatory advantages including accelerated review pathways, market exclusivity extensions, and reduced clinical trial requirements compared to more common conditions. For (ASX: NTI), the absence of approved therapies creates a clear unmet medical need and favourable commercial landscape if NTI164 gains regulatory approval.

How Effective is NTI164 for Treating PANS in Children?

The published study demonstrated that NTI164 was well tolerated across the 12-week treatment period, with no serious adverse events reported. The only side effects observed were mild, self-limiting gastrointestinal effects or fatigue, which resolved without intervention.

Clinical efficacy data showed statistically significant improvements across all major disease domains measured in the study. The breadth of response across multiple symptom categories distinguishes NTI164 from single-target therapies that address isolated symptoms.

The Clinical Global Impression – Severity (CGI-S) scale measures overall disease severity as assessed by clinicians. The improvement from 4.8 to 3.3 represents a shift from moderate-severe illness toward the mild-moderate range, indicating meaningful functional improvement.

The statistical significance values (p-values) indicate the probability that observed improvements occurred by chance. Values below p = 0.05 are considered statistically significant, with lower values indicating stronger evidence of true treatment effect. The anxiety measure (RCADS-P) achieved the strongest statistical significance at p < 0.0001, followed by obsessive-compulsive symptoms and tics.

From an investment perspective, broad-spectrum efficacy across multiple symptom domains strengthens the commercial profile by addressing the full disease burden rather than requiring combination therapy with other medications.

What Are the Results of Neurotech’s PANS Clinical Trial? The Mechanistic Breakthrough

The published study goes beyond demonstrating clinical efficacy by identifying the specific biological mechanisms through which NTI164 exerts its therapeutic effects. This mechanistic understanding provides scientific validation for the observed clinical improvements.

What the Science Revealed

Researchers employed five advanced analytical techniques to examine biological changes at the molecular level: bulk RNA sequencing, single-cell RNA sequencing, proteomics, phosphoproteomics, and DNA methylation profiling. This multi-omics approach revealed that children with PANS exhibit widespread dysregulation across three major biological pathway categories:

1. Epigenetic machinery (chromatin structure, DNA methylation, transcription factors)
2. Ribosomal and translational pathways (protein synthesis machinery)
3. Immune and inflammatory signalling networks (cytokine production, defence responses)

Epigenetic machinery refers to biological systems that control how genes are switched on or off without changing the underlying DNA sequence. Chromatin structure determines whether genes are accessible for activation, whilst DNA methylation and transcription factors regulate which genes produce proteins at any given time. Dysregulation in these systems can cause inappropriate gene expression patterns.

Ribosomal pathways control protein synthesis within cells. Ribosomes are cellular structures that translate genetic instructions into functional proteins. When these pathways malfunction, cells cannot produce the correct proteins in appropriate quantities, affecting all cellular functions.

How NTI164 Restores Biological Balance

Following 12 weeks of NTI164 treatment, the same dysregulated pathways identified in PANS patients showed significant normalisation. The treatment induced coordinated changes across multiple biological systems:

• Restoration of ribosomal function, improving cellular protein synthesis capacity
• Normalisation of mitochondrial function, enhancing cellular energy production
• Modulation of cytokine production, reducing inflammatory signalling
• Regulation of defence signalling pathways, rebalancing immune responses

The mechanistic data demonstrates that NTI164 does not simply suppress symptoms, but rather addresses underlying biological dysfunction. This distinction has material implications for intellectual property protection, as patents can claim specific pathway modulation rather than general symptom relief.

For investors, mechanistic understanding supports biomarker development. Identifying which biological markers predict treatment response enables more efficient clinical trial design by enriching patient populations with those most likely to benefit. This reduces trial costs and increases probability of regulatory success.

The pathway data also provides scientific rationale for expanding NTI164 into other paediatric neuroimmune conditions characterised by similar biological dysregulation, supporting a platform development strategy rather than single-indication focus.

Beyond PANS: What This Means for Neurotech’s Broader Pipeline

Neurotech is developing NTI164 across multiple paediatric neurological indications characterised by immune dysregulation and neuroinflammation. The mechanistic insights from the PANS publication provide biological rationale for efficacy across this broader indication suite.

The company has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD), with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. This represents the most advanced development programme within Neurotech’s pipeline.

The full NTI164 development portfolio includes:

• Autism Spectrum Disorder (ASD): Phase II/III trial complete with statistically significant, clinically meaningful results
• PANDAS/PANS: Phase I/II trials complete with statistically significant and clinically meaningful outcomes
• Rett Syndrome: Phase I/II trials complete
• Spastic cerebral palsy: Ethics committee clearance received for Phase I/II trial commencement

The mechanistic data from the PANS trial strengthens the scientific foundation for this multi-indication approach. If immune dysregulation, epigenetic dysfunction, and ribosomal pathway abnormalities represent common biological features across these conditions, NTI164’s demonstrated ability to normalise these pathways provides a unifying mechanistic explanation for observed clinical effects.

From a commercial perspective, a platform approach targeting multiple paediatric neurological conditions with a single drug candidate offers several advantages: shared regulatory learnings across programmes, potential for accelerated approval pathways based on existing safety data, and broader market opportunity compared to single-indication development.

Investment Thesis Snapshot

The Neurotech NTI164 PANS publication in Neurotherapeutics strengthens the investment case across multiple dimensions:

1. Scientific validation: Peer review by independent experts in a high-impact journal (Impact Factor 6.9) validates data quality and scientific rigour, reducing perceived technical risk.

2. Regulatory pathway: Mechanistic understanding of biological pathway modulation supports orphan drug applications and provides substantive evidence for regulatory discussions. PANS has no approved treatments, positioning NTI164 for potential accelerated review pathways.

3. Partnership value: Published data in a respected scientific journal enhances attractiveness to pharmaceutical partners conducting due diligence. Mechanistic data demonstrates reproducible, explainable therapeutic mechanism rather than empirical symptom relief.

4. Platform potential: Identification of specific dysregulated pathways that NTI164 normalises provides scientific rationale for expansion into multiple paediatric neuroimmune conditions characterised by similar biological dysfunction.

5. Market exclusivity: PANS represents an orphan indication with regulatory advantages including extended market exclusivity periods, reduced clinical trial requirements, and potential for accelerated approval pathways.

The publication transforms NTI164 from a promising clinical-stage asset with positive trial results into a scientifically validated therapeutic candidate with demonstrated mechanism of action, published in peer-reviewed literature. This progression materially de-risks the development pathway and strengthens the company’s negotiating position in potential partnership discussions.

Next Steps and Catalysts

The peer-reviewed publication supports ongoing regulatory strategy discussions by providing independently validated clinical and mechanistic evidence. The mechanistic insights enable biomarker development, which can improve patient selection in future trials and support personalised medicine approaches.

The published data strengthens the foundation for potential pharmaceutical partnership discussions by demonstrating scientific credibility through independent peer review. The mechanistic understanding of how NTI164 modulates specific biological pathways provides intellectual property advantages and supports expansion into additional paediatric neuroimmune indications characterised by similar pathway dysregulation.

Neurotech continues to advance its broader NTI164 development programme across multiple paediatric neurological conditions, with the PANS mechanistic data providing scientific rationale for the platform approach targeting immune and epigenetic dysfunction.

Want more Biotech insights?

Stay ahead in the biotech sector with the free Big News Blast email service delivering breaking news and in-depth analysis tailored to non-resource ASX sectors. Join over 20,000 active investors who rely on timely alerts and comprehensive insights to inform their strategies. To receive these expert updates, simply click the “Free Alerts” button in the site header or banner and subscribe today via StockWire X.